Drug Profile
CO 102862
Alternative Names: V 102862Latest Information Update: 29 Aug 2007
Price :
$50
*
At a glance
- Originator Purdue Pharma
- Class Antiepileptic drugs; Neuroprotectants
- Mechanism of Action Sodium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Epilepsy; Neuropathic pain
Most Recent Events
- 23 Dec 2002 Phase-I clinical trials in Epilepsy in USA (PO)
- 16 Nov 1999 CoCensys has been acquired by Purdue Pharma
- 24 Nov 1998 Preclinical development for Neuropathic pain in USA (PO)